Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Valid MeSH Conditions
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, multicenter, randomized, open-label, umbrella superiority clinical trial for patients with advanced metastatic esophageal squamous cell carcinoma who have not received prior anti-tumor treatment.
- Trial name
- NCT07709533
- Testing
- Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor
- Where
- China
- Volunteers
- 347 people
- Sponsor
- Sun Yat-sen University
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Carcinoma, Squamous Cell
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
The purpose of this study is to determine whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma.
- Trial name
- NCT02743832
- Testing
- Resection for primary lesion and cervical lymph node dissection, Resection for primary lesion only
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Jinsong Hou
Head and Neck Cancer
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
This open-label, multicenter study will evaluate the safety, tolerability, and pharmacokinetics of MEHD7945A in combination with chemotherapy (either cisplatin plus 5-FU or carboplatin plus paclitaxel) in participants with…
- Trial name
- NCT01911598
- Testing
- 5-FU, Carboplatin, Cisplatin
- Where
- 6 sites in United States, Belgium
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma patients.
- Trial name
- nabPCESCC (NCT01258192)
- Testing
- albumin-bound paclitaxel plus cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
- Trial name
- NCT03602911
- Testing
- The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- West Virginia University
Head and Neck Cancer
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Fruit and vegetable extracts may be effective in preventing the recurrence or further development of…
- Trial name
- NCT00064298
- Testing
- fruit and vegetable extracts
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- Wake Forest University Health Sciences
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck
- Trial name
- APA (NCT02573493)
- Testing
- nab-Paclitaxel, Cisplatin, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Oral Cavity Squamous Cell Carcinoma
Biofeedback Rehabilitation to Improve Speaking and Eating in Public
Tongue cancer requires resection and reconstruction that can leave patients disabled with respect to speaking and eating. Impairment of tongue function can have significant impact on social interaction and employment.
- Trial name
- Biofeedback (NCT03650699)
- Testing
- Electropalatography Biofeedback Training
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients.
- Trial name
- HENEPET (NCT04196985)
- Testing
- PET/MRI, PET/CT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Carcinoma, Squamous Cell of Head and Neck, Tobacco Use Disorder
Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer
Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosa of the upper aero-digestive tract. They are the 6th most prevalent type of cancer worldwide.
- Trial name
- INTENT (NCT03788785)
- Testing
- Experimental arm, Control arm
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Skin Melanoma, Squamous Non-small-cell Lung Cancer
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and pharmacodynamics of the drug RPH-075 (international…
- Conditions
- Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06307093
- Testing
- RPH-075, Keytruda®
- Where
- 23 sites in Russia
- Volunteers
- 90 people
- Sponsor
- R-Pharm
Head and Neck Squamous Cell Carcinoma
TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study
Primary objectives: 1. Evaluate the feasibility of rapidly accruing 30 participants with recurrent metastatic head and neck squamous cell carcinoma for the development of patient derived xenographs (PDX) from fresh, real time…
- Trial name
- Xenograft (NCT02752932)
- Testing
- Drug testing on PDX per Investigator's choice (upto 4)
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and…
- Conditions
- Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment
- Trial name
- NCT07445048
- Testing
- Bemcentinib, Nimotuzumab, radiotherapy
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Cancer
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00265941
- Testing
- cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost
- Where
- 372 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Radiation Therapy Oncology Group
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a…
- Trial name
- NCT06052839
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dan Zandberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.